HGF and liver disorder: HGF/SF-MET signalling is essential for liver development (Schmidt et al, 1995; Uehara et al, 1995) and regeneration (Borowiak et al, 2004; Huh et al, 2004; Liu, 2004) and pre-clinical studies employing either recombinant HGF/SF (Horiguchi et al, 2009), HGF/SF gene delivery (Ueki et al, 1999) or HGF/SF-transfected mesenchymal stem cells (Moon et al, 2019) all demonstrated a strong therapeutic potential for HGF/SF in pre-clinical models of liver diseases.